Henry Schein has acquired a majority ownership stake in France-based dental supply group Biotech Dental.
Biotech will maintain its own brands and go-to-market strategies and continue to be led by Founder and President Philippe Veran, according to a Dec. 16 news release from Henry Schein.
Over time, Henry Schein plans to incorporate Biotech's Nemotec planning and diagnostic software with Henry Schein One's practice management software, Stanley Bergman, chair of the board and CEO of Henry Schein, said in the release.
Biotech Dental manufactures implants, implant treatment planning software, orthodontic aligners, and regenerative and digital dentistry products.